4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)

4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)

4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)

4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)

4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)

4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)

4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)

4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)

4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)

4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)

EFFECT - Elicio Therapeutics, Inc. (0001601485) (Filer)

S-3 - Elicio Therapeutics, Inc. (0001601485) (Filer)

10-Q - Elicio Therapeutics, Inc. (0001601485) (Filer)

8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)

8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)

8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)

10-Q - Elicio Therapeutics, Inc. (0001601485) (Filer)

8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)

8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)

8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)

Antigen spreading was evaluated in a subset of Phase 2 patients to assess the ability of ELI-002 7P to broaden immune responses to personalized tumor neoantigens not present in the targeted immunotherapy87% (13/15) of evaluated patients demonstrated induction of T cell responses to tumor neoantigens beyond mKRAS following ELI-002 7P therapyThe induction of non-mKRAS antigen-specific T cell responses supports the potential for ELI-002 7P to generate a broader, more adaptable, and personalized anti-tumor response BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company")), a clinical-stage biotechnology company developing a pipeline of novel

BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Marc J. Wolfgang, M.S. as Chief Technology Officer ("CTO"). Mr. Wolfgang brings more than 30 years of biopharmaceutical leadership spanning manufacturing, CMC strategy, development, quality, and supply chain across modalities including cell therapy, biologics, nucleic-acid medicines, vaccines, and LNP platforms. He most recently served as Senior Vice President of Technical Development and Operations at Sail Biomedicines (a Flagship

In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma ("PDAC"), fewer disease progressions and deaths than projected have been observed as of November 6, 2025. Based on 2:1 randomization with twice as many patients in the ELI-002 7P treatment arm compared to the observation arm, Elicio believes the lower-than-projected number of disease progressions and deaths may reflect a favorable impact on disease-free survival ("DFS"); event-driven primary DFS analysis now anticipated in 1H 2026.Since the beginning of Q3 2025, the Company has raised gross proceeds of approximately $11.1 million through its established at-the-market program, exten

SITC abstracts highlight updated immunogenicity results from the Phase 2 AMPLIFY-7P trial of ELI-002 7P and preclinical data on the use of intratumoral ELI-004 (AMP-CpG) for solid tumor immunotherapyELI-002 7P induced mKRAS-specific T cell responses in 99% of evaluable patients (89/90), demonstrating potent and consistent immune activationRobust immune responses were elicited across all seven mKRAS antigens, with >80% response rate to each individual KRAS mutation and 88% of patients generating responses to their own tumor-specific mutation86.8% (66/76) of patients induced cytotoxic mKRAS-specific T cell responses; 75% (57/76) induced CD8+ T cells and 75% (57/76) induced CD4+ T cellsmKRAS-sp

BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that the Company will present a late-breaking update on clinical immunogenicity results from its ongoing Phase 2 AMPLIFY-7P trial of ELI-002 in patients with mKRAS-driven pancreatic cancer and preclinical data from ELI-004 for the treatment of advanced solid tumors via two accepted poster presentations at the Society for Immunotherapy of Cancer's ("SITC") 40th Anniversary Annual Meeting, taking place November 5–9, 2025, in National Harbor, Maryland. P

ELI-002 7P demonstrated robust mKRAS-specific T cell responses across a broad range of HLA types, highlighting its potential for use among a diverse patient populationPatients treated with ELI-002 7P represented a diverse HLA repertoire including 1,132 unique types identified among 1,398 total HLA backgrounds in assessed patients99% (88/89) of patients assessed for HLA background induced mKRAS-specific T cell responses after treatment with ELI-002 7PInduction of mKRAS-specific T cell responses suggest that ELI-002 7P may address a broad patient population with high unmet need for pancreatic ductal adenocarcinoma ("PDAC") BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc.

Study will evaluate ELI-002 7P in combination with chemotherapy and a checkpoint inhibitor ("CPI") in the neoadjuvant settingTrial is anticipated to begin enrolling in H1'2026 BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the planned initiation of an investigator-initiated Phase 1 neoadjuvant study of ELI-002 7P in combination with chemotherapy and an anti-PD1 checkpoint inhibitor in borderline and resectable pancreatic ductal adenocarcinoma ("PDAC"). The multi-center investigator-initiated tria

BOSTON, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on September 15, 2025, Elicio granted an aggregate of 9,800 inducement stock options to two new employees, as an inducement material to each individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock options were approved by the Compensation Committee of Elicio's Board of Directors and granted under the Elicio Therapeutics, Inc. 2024 Inducement Incentive Award Plan. Each grant provides

ELI-002 induced mKRAS-specific T cell responses in 99% of evaluable patients (89 of 90) who were treated with the investigational vaccine immunotherapyRobust mKRAS-specific T cell responses were observed with an average of 145.3x increase over baseline (median 44.3x; range 2.13-1310x), consistent with prior ELI-002 Phase 1 trial resultsT cell responses included both mKRAS-specific CD4 and CD8 T cells in 85% of patients BOSTON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced immunogenicity testing data sho

At extended median follow-up of 19.7 months, median overall survival ("OS") increased from 16.33 to 28.94 months Clinical efficacy correlated with the magnitude of T cell responses specific to mutant-KRAS ("mKRAS") induced by ELI-00277% reduction in the risk of death and 88% reduction in the risk of relapse, associated with T cell responses above the threshold for anti-tumor efficacyELI-002 induced both CD4+ and CD8+ mKRAS-specific T cell responses in most patients, and evidence of antigen-spreading to patient-specific neoantigens not included in ELI-002 was observed Final event-driven disease-free survival ("DFS") analysis for the randomized Phase 2 AMPLIFY-7P study evaluating ELI-002 7P mo

BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Marc J. Wolfgang, M.S. as Chief Technology Officer ("CTO"). Mr. Wolfgang brings more than 30 years of biopharmaceutical leadership spanning manufacturing, CMC strategy, development, quality, and supply chain across modalities including cell therapy, biologics, nucleic-acid medicines, vaccines, and LNP platforms. He most recently served as Senior Vice President of Technical Development and Operations at Sail Biomedicines (a Flagship

BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio Therapeutics" or "Elicio")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer, effective as of the date hereof. Dr. Shah brings a wealth of leadership experience to Elicio after previously serving as chief financial officer, chief business officer, and in other senior leadership roles at multiple publicly traded biotechnology companies. "We are pleased to welcome Preetam to Elicio's executive team," said Robert Connelly, Ph.D., Preside

BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics. Ms. Filoon will oversee all company legal affairs including corporate governance and compliance functions. Dr. Kheoh will provide biostatistical leadership and strategic guidance into the development of the Company's product candidate portfolio including the ongoing AMPLIFY-201 and AMPLIFY-7P trials of the lead asset, ELI-002. "Megan and Thian are joining us at an exc

SC 13D/A - Elicio Therapeutics, Inc. (0001601485) (Subject)

SC 13D/A - Elicio Therapeutics, Inc. (0001601485) (Subject)

SC 13D/A - Elicio Therapeutics, Inc. (0001601485) (Subject)

SC 13D/A - Elicio Therapeutics, Inc. (0001601485) (Subject)

SC 13D/A - Elicio Therapeutics, Inc. (0001601485) (Subject)